Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfampridine-ER in Chronic Deficits After Ischemic Stroke
NCT01605825Phase 2Completed
- Sponsor
- Acorda Therapeutics
- Start
- May 2012
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dalfampridine in ischemic stroke (2 arms), sponsored by Acorda Therapeutics. Primary endpoint: Treatment Emergent Adverse Events at 36 days. Started May 2012; status: completed.
02
Drugs
dalfampridine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01605825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605825.